AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider David Epstein Buys 5,000 Shares

Key Points

• Director David Epstein bought 5,000 shares of AgomAb Therapeutics at $8.70 each, investing $43,500 and doubling his direct ownership to 10,000 shares.
• AGMB opened at $8.84 after rising 1.7%, but remained below its 50-day and 200-day moving averages of $12.82 and $12.00, respectively. The stock’s 52-week range is $7.97 to $17.82.
• Analysts maintain a generally positive outlook, with seven Buy ratings and one Hold, producing a “Moderate Buy” consensus and an average price target of $37.50; the company is developing antibody-based therapies, including AGMB-129 for inflammatory bowel disease.

AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) Director David Epstein acquired 5,000 shares of AgomAb Therapeutics stock in a transaction that occurred on Tuesday, October 6th. The stock was acquired at an average price of $8.70 per share, with a total value of $43,500.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at $87,000. This represents a 100.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

AgomAb Therapeutics Trading Up 1.7%

NASDAQ:AGMB opened at $8.84 on Wednesday. The business's fifty day moving average is $12.82 and its 200 day moving average is $12.00. AgomAb Therapeutics NV has a 52-week low of $7.97 and a 52-week high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Research analysts forecast that AgomAb Therapeutics NV will post -1.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AGMB. Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They set an "overweight" rating for the company. B. Riley Financial initiated coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They set a "buy" rating and a $34.00 price objective for the company. Piper Sandler initiated coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an "overweight" rating and a $60.00 target price on the stock. HC Wainwright restated a "buy" rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Finally, Wall Street Zen lowered shares of AgomAb Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, September 27th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab's lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.